APOC3 and metabolic syndrome: Thirdly, the current evidence on PCSK9 editing opens the stage for other genetically validated treatment targets in dyslipidemia such as lipoprotein(a), angiopoietin-like 3, and apolipoprotein CIII which can already be silenced with antisense-oligonucleotides and siRNA [18].